The positive cardiovascular outcomes trials (CVOT) for SGLT-2 inhibitor Jardiance and GLP-1 agonist Victoza have generated a great deal of enthusiasm at scientific conferences. To gauge the views of primary care physicians (PCPs), Biomedtracker/Datamonitor Healthcare conducted an eight-question survey of 26 PCPs who were already familiar with the data, and to confirm interesting findings, 25 additional PCPs who are currently low users of SGLT-2 inhibitors.

Jardiance’s PDUFA for a CV indication is expected on December 2, 2016, but even that is not granted this time around, it should come once the results are duplicated by another SGLT-2 inhibitor.

If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.